The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey

Bulur, Isil; BÜLBÜL BAŞKAN, EMEL; Ozdemir, Mustafa; Balevi, Ali; Goncu, Emek; Altunay, Ilknur; Gonul, Muzeyyen; Ergin, Can; ERTAM SAĞDUYU, İLGEN; KAYA ERDOĞAN, HİLAL; BİLGİN, MUZAFFER; Erdem, Mustafa

doi:10.15570/actaapa.2018.25

The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey

Bulur I., BÜLBÜL BAŞKAN E., Ozdemir M., Balevi A., Goncu E. K., Altunay I., ...Daha Fazla

ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, cilt.27, sa.3, ss.121-126, 2018 (ESCI, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 27 Sayı: 3
Basım Tarihi: 2018
Doi Numarası: 10.15570/actaapa.2018.25
Dergi Adı: ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.121-126
Anahtar Kelimeler: chronic spontaneous urticaria, omalizumab, dermatology life quality, UAS(7), side effects, QUALITY-OF-LIFE, INDUCIBLE URTICARIA, DISEASE-ACTIVITY, THERAPY, VALIDATION, MANAGEMENT, INDEX, IGE
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients.